Renew Biopharma is a Delaware C Corporation based in San Diego, California, that was founded in 2017 by Michael Mendez. Michael Mendez is also the CEO of Renew BioPharma with more than 20 years of experience working in the synthetic biology industry. The company is focused on creating a pipeline of 100 percent pure, uncontaminated and non-psychoactive cannabinoids in quantities large enough to enable human therapeutic treatments. Renew uses molecular biology and pathway engineering instead of using agriculturally-grown Cannabis plants. Renew has a proprietary family of pharmacological chemical compounds - cannabinoids - specifically pure forms of CBG (cannabigerol) and CBD (cannabidiol). Renew's intellectual property includes both specific genes in the biosynthesis of cannabinoids and the ability to engineer a synthetic cannabinoid pathway into microorganisms, including microalgae.
Renew BioPharma possesses intellectual property and technological capabilities related to engineering enzymes for creating proprietary derivative molecules for the development of pharmaceutical drugs.
Renew Biopharma Launches Pre-Clinical Drug Discovery Program with Indiana University Bloomington's Gill Center for Biomolecular Science Using Cannabinoids Grown in Microalgae
Documentaries, videos and podcasts
October 29, 2018
- Synthetic biologyInterdisciplinary branch of biology and engineering, applying multiple disciplines to build artificial biological systems for research, engineering, and medical applications.
- CannabisCannabis is a genus of flowering plants in the family Cannabaceae. The number of species within the genus is disputed. Three species may be recognized: Cannabis sativa, Cannabis indica, and Cannabis ruderalis.
- BiopharmaceuticalType of pharmaceutical drug product